Molecular profiling of Parkinson's disease

Molecular profiling of Parkinson's disease - Molecular profiling of Parkinson's disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39947

Enrollment

100

Registered

2012-11-13

Start date

2013-02-06

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For all participants a minimum age of 18 years is required. All patients with Parkinson's Disease (PD) must fulfill the United Kingdom Parkinson's Disease Society Brain Bank criteria for idiopathic PD. Patients with Dementia with Lewy Bodies (DLB) must fulfill the McKeith DLB criteria and all patients must be diagnosed with PD or DLB by a movement disorder specialist. All participants must be able to give informed consent. Buffy coats of controls are included if they have no diseases of the central nervous system or conditions associated with the immune system.

Exclusion criteria

Exclusion criteria: Participants should have no inflammatory diseases. Participants are excluded when anti-inflammatory drugs (NSAIDs, corticosteroids), immunosuppressive medication or anti-oxidants (Vitamin C) are used. Participants are excluded when having an infectious disease at the time of the measurements. Participants who currently smoke are excluded. Patients who underwent stereotactic surgery are excluded.

Design outcomes

Primary

Measure	Time frame
The main parameters of this study are the redox responses to pro-oxidant challenge tests and bioenergetics functions such as mitochondrial respiration and glycolytic activity. All patient groups will be characterized on environmental exposures (smoking, insecticides, herbicides). For redox susceptibility profiling, 20 ml blood will be drawn via venapuncture and a skin biopsy will be performed. Differences in redox response to toxin challenge will be determined in peripheral blood cells and induced pluripotent stem cells by differential labelling of reduced and oxidized cysteines residues with maleimide technology followed by Fluorescence Assisted Cell Sorting (FACS) analysis.	—

Measure

Time frame

The main parameters of this study are the redox responses to pro-oxidant challenge tests and bioenergetics functions such as mitochondrial respiration and glycolytic activity. All patient groups will be characterized on environmental exposures (smoking, insecticides, herbicides). For redox susceptibility profiling, 20 ml blood will be drawn via venapuncture and a skin biopsy will be performed. Differences in redox response to toxin challenge will be determined in peripheral blood cells and induced pluripotent stem cells by differential labelling of reduced and oxidized cysteines residues with maleimide technology followed by Fluorescence Assisted Cell Sorting (FACS) analysis.

—

Secondary

Measure	Time frame
Clinical assessments will be used to assess the progression of the core features of PD, which is necessary to allocate patients to one of the subgroups. The patients with DLB will be assessed clinically to be able to compare the clinical function of PD and DLB patients.	—

Countries

Netherlands

Outcome results